Angelena Crown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Angelena Crown has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amanda L. Kong
Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, USA
1 shared publication - Claire Buchanan
Breast Surgery Division, True Family Women's Cancer Center, Swedish Cancer Institute, 1221 Madison Street, Suite 600, Seattle, WA, 98104, USA
1 shared publication - Damian McCartan
Department of Surgery Waterford Regional Hospital Dunmore Road Waterford Republic of Ireland
1 shared publication - Mary L. Gemignani
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Michael Curry
Memorial Sloan Kettering Cancer Center , New York, NY
1 shared publication - Sabrina Kamer
Department of Obstetrics and Gynecology, Albany Medical Center, Albany, USA
1 shared publication
Latest Publications
- 16 October 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 240, 116013
Unveiling the disparities within: Why we need to disaggregate data for Asian women with breast cancer
- 16 October 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 240, 116013
Unveiling the disparities within: Why we need to disaggregate data for Asian women with breast cancer
- 20 January 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 283-294
Pregnancy-associated breast cancer: does timing of presentation affect outcome?
Purpose Pregnancy-associated breast cancer (PABC) comprises breast cancer diagnosed during the gestational period or within 12 months postpartum. While the incidence of PABC appears to be increasing, data regarding prognosis remain limited. Methods Here we evaluate clinicopathologic features, treatments, and clinical outcomes among women with stage 0-III PABC diagnosed between 1992 and 2020. Comparisons were made between women who were diagnosed with PABC during gestation and those who were diagnosed within 12 months postpartum. Results A total of 341 women were identified, with a median age of 36 years (range 25–46). The pregnancy group comprised 119 (35%) women, while 222 (65%) women made up the postpartum group. Clinicopathologic features were similar between groups, with most patients being parous and presenting with stage I and II disease. Treatment delays were uncommon, with a median time from histologic diagnosis to treatment of 4 weeks for both groups. Recurrence-free survival was similar between groups: 67% at 10 years for both. While 10-year overall survival appeared higher in the postpartum group (83% versus 78%, p = 0.02), only the presence of nodal metastases was associated with an increased risk of death (hazard ratio 5.61, 95% CI 2.20–14.3, p < 0.001), whereas timing of diagnosis and receptor profile did not reach statistical significance. Conclusion Clinicopathologic features of women with PABC are similar regardless of timing of diagnosis. While 10-year recurrence-free survival is similar between groups, 10-year overall survival is higher among women diagnosed postpartum; however, timing of diagnosis may not be the driving factor in determining survival outcomes.
- 20 January 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 283-294
Pregnancy-associated breast cancer: does timing of presentation affect outcome?
Purpose Pregnancy-associated breast cancer (PABC) comprises breast cancer diagnosed during the gestational period or within 12 months postpartum. While the incidence of PABC appears to be increasing, data regarding prognosis remain limited. Methods Here we evaluate clinicopathologic features, treatments, and clinical outcomes among women with stage 0-III PABC diagnosed between 1992 and 2020. Comparisons were made between women who were diagnosed with PABC during gestation and those who were diagnosed within 12 months postpartum. Results A total of 341 women were identified, with a median age of 36 years (range 25–46). The pregnancy group comprised 119 (35%) women, while 222 (65%) women made up the postpartum group. Clinicopathologic features were similar between groups, with most patients being parous and presenting with stage I and II disease. Treatment delays were uncommon, with a median time from histologic diagnosis to treatment of 4 weeks for both groups. Recurrence-free survival was similar between groups: 67% at 10 years for both. While 10-year overall survival appeared higher in the postpartum group (83% versus 78%, p = 0.02), only the presence of nodal metastases was associated with an increased risk of death (hazard ratio 5.61, 95% CI 2.20–14.3, p < 0.001), whereas timing of diagnosis and receptor profile did not reach statistical significance. Conclusion Clinicopathologic features of women with PABC are similar regardless of timing of diagnosis. While 10-year recurrence-free survival is similar between groups, 10-year overall survival is higher among women diagnosed postpartum; however, timing of diagnosis may not be the driving factor in determining survival outcomes.
- 1 February 2022
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (2) , 436-437
My surgical practice: Presenting aesthetic flat closure as an equal option to mastectomy with reconstruction and technical considerations to optimize cosmesis
- 1 February 2022
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (2) , 436-437
My surgical practice: Presenting aesthetic flat closure as an equal option to mastectomy with reconstruction and technical considerations to optimize cosmesis